Literature DB >> 18497537

Survival in familial pancreatic cancer.

Jianguang Ji1, Asta Forsti, Jan Sundquist, Per Lenner, Kari Hemminki.   

Abstract

BACKGROUND: Family history has been reported to be associated with an increased risk of pancreatic cancer. However, its possible influence on pancreatic cancer survival has rarely been studied, probably because of the rareness of cases in the same family.
METHODS: We used the nationwide Swedish Family-Cancer Database to examine the survival differences between familial and sporadic pancreatic cancers. Hazard ratios (HRs) for cause-specific and overall survival in pancreatic cancer were examined. HRs show the probability of death in the study group compared to the reference group.
RESULTS: A total of 75 familial pancreatic cancers were noted. HRs were significantly higher among offspring with an affected parent compared to those without an affected parent; for cause-specific and overall survival, the HRs were 1.44 and 1.37, respectively. Reversing the analysis and deriving HRs for parents (offspring as probands) showed that familial pancreatic cancer had a worse prognosis than sporadic cases (HR 1.37 for cause-specific and 1.28 for overall survival). The HRs were close to unity among spouses with concordant pancreatic cancer.
CONCLUSION: The data show that survival in familial pancreatic cancer is worse than that in sporadic disease, which could be explained by genetic factors, if other confounding factors can be excluded. and IAP. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18497537     DOI: 10.1159/000134272

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

Review 1.  Genetic insights into the morass of metastatic heterogeneity.

Authors:  Kent W Hunter; Ruhul Amin; Sarah Deasy; Ngoc-Han Ha; Lalage Wakefield
Journal:  Nat Rev Cancer       Date:  2018-02-09       Impact factor: 60.716

2.  Familial and sporadic pancreatic cancer share the same molecular pathogenesis.

Authors:  Alexis L Norris; Nicholas J Roberts; Siân Jones; Sarah J Wheelan; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Alison P Klein; James R Eshleman
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

Review 3.  Familial pancreatic cancer: Concept, management and issues.

Authors:  Hiroyuki Matsubayashi; Kyoichi Takaori; Chigusa Morizane; Hiroyuki Maguchi; Masamichi Mizuma; Hideaki Takahashi; Keita Wada; Hiroko Hosoi; Shinichi Yachida; Masami Suzuki; Risa Usui; Toru Furukawa; Junji Furuse; Takamitsu Sato; Makoto Ueno; Yoshimi Kiyozumi; Susumu Hijioka; Nobumasa Mizuno; Takeshi Terashima; Masaki Mizumoto; Yuzo Kodama; Masako Torishima; Takahisa Kawaguchi; Reiko Ashida; Masayuki Kitano; Keiji Hanada; Masayuki Furukawa; Ken Kawabe; Yoshiyuki Majima; Toru Shimosegawa
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

4.  The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival.

Authors:  Mohamad Dbouk; Bryson W Katona; Randall E Brand; Amitabh Chak; Sapna Syngal; James J Farrell; Fay Kastrinos; Elena M Stoffel; Amanda L Blackford; Anil K Rustgi; Beth Dudley; Linda S Lee; Ankit Chhoda; Richard Kwon; Gregory G Ginsberg; Alison P Klein; Ihab Kamel; Ralph H Hruban; Jin He; Eun Ji Shin; Anne Marie Lennon; Marcia Irene Canto; Michael Goggins
Journal:  J Clin Oncol       Date:  2022-06-15       Impact factor: 50.717

5.  Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors.

Authors:  Jacek A Smigielski; Lukasz Piskorz; Marcin Wawrzycki; Przemysław Dobielski; Małgorzata Pikala; Sławomir Jabłoński; Marian Brocki
Journal:  Arch Med Sci       Date:  2013-08-08       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.